These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8258620)

  • 21. The pathophysiology of rhinitis. V. Sources of protein in allergen-induced nasal secretions.
    Raphael GD; Igarashi Y; White MV; Kaliner MA
    J Allergy Clin Immunol; 1991 Jul; 88(1):33-42. PubMed ID: 1712803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge.
    Wang D; Smitz J; Waterschoot S; Clement P
    Allergy; 1997 Feb; 52(2):162-7. PubMed ID: 9105520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Females have stronger neurogenic response than males after non-specific nasal challenge in patients with seasonal allergic rhinitis.
    Tomljenovic D; Baudoin T; Megla ZB; Geber G; Scadding G; Kalogjera L
    Med Hypotheses; 2018 Jul; 116():114-118. PubMed ID: 29857893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration.
    Proud D; Reynolds CJ; Lichtenstein LM; Kagey-Sobotka A; Togias A
    Clin Exp Allergy; 1998 Jul; 28(7):868-75. PubMed ID: 9720821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Humoral mucosal immunity in allergic rhinitis].
    Kramer MF; Jordan TR; Pfrogner E; Rasp G
    Laryngorhinootologie; 2005 Jul; 84(7):503-10. PubMed ID: 16010632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis.
    Guyer BJ; Shimamoto SR; Bradhurst AL; Grossbard EB; Dreskin SC; Nelson HS
    Allergy Asthma Proc; 2006; 27(3):208-13. PubMed ID: 16913263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nasal hyperosmolar challenge with a dry powder of mannitol in patients with allergic rhinitis. Evidence for epithelial cell involvement.
    Koskela H; Di Sciascio MB; Anderson SD; Andersson M; Chan HK; Gadalla S; Katelaris C
    Clin Exp Allergy; 2000 Nov; 30(11):1627-36. PubMed ID: 11069573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure.
    Wang D; Clement P; Smitz J; De Waele M; Derde MP
    Int Arch Allergy Immunol; 1995 Mar; 106(3):278-85. PubMed ID: 7888790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal allergen challenge and immunotherapy control.
    Palma-Carlos AG; Palma-Carlos ML; Branco-Ferreira M; Spinola A; Santos MC; Lopes-Pregral A
    Allerg Immunol (Paris); 1998 May; 30(5):153-6. PubMed ID: 9657024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergic rhinitis: not purely a histamine-related disease.
    Howarth PH; Salagean M; Dokic D
    Allergy; 2000; 55 Suppl 64():7-16. PubMed ID: 11291780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologic responses and histamine release after nasal antigen challenge. Effect of atropine.
    Baroody FM; Ford S; Lichtenstein LM; Kagey-Sobotka A; Naclerio RM
    Am J Respir Crit Care Med; 1994 Jun; 149(6):1457-65. PubMed ID: 7516250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of nedocromil sodium on allergen-induced rhinitis in humans.
    Kaulbach HC; Igarashi Y; Mullol J; White MV; Kaliner MA
    J Allergy Clin Immunol; 1992 Feb; 89(2):599-610. PubMed ID: 1311008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metachromatic, IgE-bearing and tryptase-containing cells on the nasal mucosal surface in provoked allergic rhinitis.
    Juliusson S; Karlsson G; Bachert C; Enerbäck L
    APMIS; 1994 Feb; 102(2):153-60. PubMed ID: 8167011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy and mast cell activation.
    Carlos AG; Carlos ML; Santos MA; Pedro E; Santos S; Lopes-Pregal A
    Allerg Immunol (Paris); 1998 Oct; 30(8):257-8. PubMed ID: 9846195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
    Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
    Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnosis of allergic rhinitis by determining of tryptase and eosinophil cationic protein in nasal secretions].
    Rasp G; Bujía J
    Acta Otorrinolaringol Esp; 1994; 45(6):437-40. PubMed ID: 7873234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasal challenge with serotonin in asymptomatic hay fever patients.
    Tønnesen P; Schaffalitzky de Muckadell OB; Mygind N
    Allergy; 1987 Aug; 42(6):447-50. PubMed ID: 2444128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pavlovian conditioning of nasal tryptase release in human subjects with allergic rhinitis.
    Gauci M; Husband AJ; Saxarra H; King MG
    Physiol Behav; 1994 May; 55(5):823-5. PubMed ID: 8022900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentrations of chemical mediators in nasal secretions of patients with hay fever during natural allergen exposure.
    Wang D; Clement P; Smitz J; Derde MP
    Acta Otolaryngol; 1994 Sep; 114(5):552-5. PubMed ID: 7825440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mediator release after nasal airway challenge with allergen.
    Naclerio RM; Meier HL; Kagey-Sobotka A; Adkinson NF; Meyers DA; Norman PS; Lichtenstein LM
    Am Rev Respir Dis; 1983 Oct; 128(4):597-602. PubMed ID: 6354022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.